Cargando…

Population pharmacokinetic data analysis of three phase I studies of matuzumab, a humanised anti-EGFR monoclonal antibody in clinical cancer development

A population pharmacokinetic model based on data from three phase I studies was to be developed including a covariate analysis to describe the concentration–time profiles of matuzumab, a novel humanised monoclonal antibody. Matuzumab was administered as multiple 1 h i.v. infusions with 11 different...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuester, K, Kovar, A, Lüpfert, C, Brockhaus, B, Kloft, C
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2008
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2266843/ https://www.ncbi.nlm.nih.gov/pubmed/18319714 http://dx.doi.org/10.1038/sj.bjc.6604265

Ejemplares similares

Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer
por: Graeven, U, et al.
Publicado: (2006)

Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer
por: Rao, S, et al.
Publicado: (2008)

Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer
por: Royer, B, et al.
Publicado: (2010)

Characterisation of a humanised bispecific monoclonal antibody for cancer therapy.
por: Bruynck, A., et al.
Publicado: (1993)

In vitro and in vivo anticancer efficacy of unconjugated humanised anti-CEA monoclonal antibodies
por: Blumenthal, R D, et al.
Publicado: (2008)

Assessment of the Pharmacokinetics and Safety of Spesolimab, a Humanised Anti-interleukin-36 Receptor Monoclonal Antibody, in Healthy Non-Japanese and Japanese Subjects: Results from Phase I Clinical Studies
por: Joseph, David, et al.
Publicado: (2022)

Reply: In vitro and in vivo anticancer efficacy of unconjugated humanised anti-CEA monoclonal antibodies
por: Ashraf, S Q, et al.
Publicado: (2008)

Humanised monoclonal antibodies neutralise pertussis toxin by receptor blockade and reduced retrograde trafficking
por: Acquaye‐Seedah, Edith, et al.
Publicado: (2018)

Efficient Blockade of Akt signaling is a determinant factor to overcome resistance to Matuzumab
por: Meira, Debora D, et al.
Publicado: (2011)

Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study
por: Steinfeld, Serge D, et al.
Publicado: (2006)

Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape
por: Colpitts, Che C, et al.
Publicado: (2018)

In vitro and in vivo anti-tumour effects of a humanised monoclonal antibody against c-erbB-2 product.
por: Tokuda, Y., et al.
Publicado: (1996)

Tumour targeting of humanised cross-linked divalent-fab′ antibody fragments: a clinical phase I/II study
por: Casey, J L, et al.
Publicado: (2002)

Nonlinear pharmacokinetics of therapeutic proteins resulting from receptor mediated endocytosis
por: Krippendorff, Ben-Fillippo, et al.
Publicado: (2009)

Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer.
por: Modjtahedi, H., et al.
Publicado: (1996)

A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45
por: Descamps, G, et al.
Publicado: (2009)

Pharmacokinetics of Monoclonal Antibodies
por: Ryman, Josiah T., et al.
Publicado: (2017)

A Species-Specific Anti-Human P2X7 Monoclonal Antibody Reduces Graft-versus-Host Disease in Humanised Mice
por: Elhage, Amal, et al.
Publicado: (2023)

Axillary node status in breast cancer patients prior to surgery by imaging with Tc-99m humanised anti-PEM monoclonal antibody, hHMFG1
por: Al-Yasi, A R, et al.
Publicado: (2002)

Recombinant humanised anti-HER2/neu antibody (Herceptin®) induces cellular death of glioblastomas
por: Mineo, J-F, et al.
Publicado: (2004)

Targeted killing of colorectal cancer cell lines by a humanised IgG1 monoclonal antibody that binds to membrane-bound carcinoembryonic antigen
por: Conaghan, P J, et al.
Publicado: (2008)

Humanising the mouse genome piece by piece
por: Zhu, Fei, et al.
Publicado: (2019)

Phase II clinical trial testing the safety of a humanised monoclonal antibody anti-CD20 in patients with heart failure with reduced ejection fraction, ICFEr-RITU2: study protocol
por: Sánchez-Trujillo, Luis, et al.
Publicado: (2019)

A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours
por: Attard, G, et al.
Publicado: (2007)

Targeting a bacterial DNABII protein with a chimeric peptide immunogen or humanised monoclonal antibody to prevent or treat recalcitrant biofilm-mediated infections
por: Novotny, Laura A., et al.
Publicado: (2020)

Co-crystallisation and humanisation of an anti-HER2 single-domain antibody as a theranostic tool
por: Sawmynaden, Kovilen, et al.
Publicado: (2023)

Nimotuzumab, an Anti-EGFR Monoclonal Antibody, in the Treatment of Nasopharyngeal Carcinoma
por: Liang, Renba, et al.
Publicado: (2021)

Cytochrome P450 humanised mice
por: Gonzalez, Frank J
Publicado: (2004)

The qualitative method for a humanisation of research
por: Artioli, Giovanna, et al.
Publicado: (2021)

Characterisation and internalisation of recombinant humanised HMFG-1 antibodies against MUC1
por: Pericleous, L M, et al.
Publicado: (2005)

Towards Translational ImmunoPET/MR Imaging of Invasive Pulmonary Aspergillosis: The Humanised Monoclonal Antibody JF5 Detects Aspergillus Lung Infections In Vivo
por: Davies, Genna, et al.
Publicado: (2017)

Safety, pharmacokinetics and efficacy of SCT200, an anti-EGFR monoclonal antibody in patients with wild-type KRAS/NRAS/BRAF metastatic colorectal cancer: a phase I dose-escalation and dose-expansion study
por: Zhang, Wen, et al.
Publicado: (2022)

Elucidation of the critical epitope of an anti-EGFR monoclonal antibody EMab-134
por: Kaneko, Mika K., et al.
Publicado: (2018)

The Role of Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy
por: Yuan, Meiqin, et al.
Publicado: (2022)

Humanising and dehumanising pigs in genomic and transplantation research
por: Lowe, James W. E.
Publicado: (2022)

Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins
por: Liu, Liming
Publicado: (2017)

On a Method of Infant-Feeding by Home-Made Humanised Milk
por: Hall, C. Beauchamp
Publicado: (1904)

EGFR expression levels affect the mode of action of EGFR-targeting monoclonal antibodies
por: Derer, Stefanie, et al.
Publicado: (2013)

EGFR monoclonal antibody panitumumab inhibits chronic proliferative cholangitis by downregulating EGFR
por: Liu, San-Hu, et al.
Publicado: (2019)

Utility of physiologically based pharmacokinetic modeling to predict inter-antibody variability in monoclonal antibody pharmacokinetics in mice
por: Liu, Shufang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3nfr8uho3ovvjcer9rdtcqt2dg